Cargando…
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
BACKGROUND: AIDS-associated cryptococcal meningitis has a high mortality. Fluconazole was the only systemic antifungal therapy available in our centre. From 1999–2001 we used low-dose fluconazole (200 mg daily initially), and did not offer therapy to patients perceived to have poor prognoses. In 200...
Autores principales: | Schaars, CF, Meintjes, GA, Morroni, C, Post, FA, Maartens, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1540428/ https://www.ncbi.nlm.nih.gov/pubmed/16846523 http://dx.doi.org/10.1186/1471-2334-6-118 |
Ejemplares similares
-
Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis
por: Molloy, Síle F., et al.
Publicado: (2018) -
A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi
por: Gaskell, Katherine M., et al.
Publicado: (2014) -
Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
por: Mpoza, Edward, et al.
Publicado: (2017) -
A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi
por: Rothe, Camilla, et al.
Publicado: (2013) -
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018)